Morphic Announces Corporate Highlights and Financial Results

-Enrollment continued on target in EMERALD-2 Phase 2b trial of MORF-057 in ulcerative colitis-

Related Keywords

Simon Cooper , Chris Erdman , Praveen Tipirneni , Key Additions To Morphic Leadership Team , Development Program , Napp Pharmaceutical Research , Exchange Commission , University Of Newcastle Upon Tyne Medical School , Morphic Holding Inc , Wyeth Research , Human Genome Sciences , Kadmon Holdings , Securities Exchange , Novartis , Chief Medical , Chief Medical Officer , Recent Corporate , Simple Endoscopic Activity Score , Morphic Leadership , Vice President , Global Project Head , Keros Therapeutics , Tyne Medical , First Quarter , Robarts Histopathology Index , Modified Mayo Clinic Score , Simple Endoscopic Score , Disease Activity Index , Securities Act , Securities Exchange Act , Private Securities Litigation Reform Act , Financial Tables , Consolidated Statements , Months Ended March , Region ,